奥沙利铂联合S-1与XELOX方案在胃癌术后辅助化疗中的临床效果比较

Adjuvant chemotherapy with Oxaliplatin plus S-1 versus XELOX regimen for postoperative gastric cancer

目的:比较奥沙利铂联合S-1与XELOX(奥沙利铂+卡培他滨)方案在胃癌术后辅助化疗中的临床效果。方法:将81例胃癌术后患者随机分入观察组(n=41)和对照组(n=40),观察组给予奥沙利铂+S-1方案化疗,对照组给予XEOLX方案化疗。结果:观察组与对照组的1,2年无复发生存率(RFS)分别为51.3%,61.5%和25.6%,20.5%;1,2年总生存率分别为64.1%和69.2%,30.8%和25.6%;差异均无统计学意义(P=0.361,0.591;P=0.631,0.615)。两组的毒副反应主要表现为骨髓抑制、胃肠道反应、手足综合征、口腔黏膜炎、末梢神经毒性及肝肾功能损伤,其中对照组手足综合征的发生率明显高于观察组(P=0.001);所有毒副反应经对症治疗后均好转。结论:奥沙利铂联合S-1与XELOX方案在胃癌术后辅助化疗中效果相当。

Objective： To compare the clinical efficacy of oxaliplatin plus tegafur-gimeracil-oteracil potassium （S-l） and XELOX （oxaliplatin＋capecitabine） regimen in adjuvant chemotherapy for postoperative gastric cancer patients. Methods： Eight-one stomach cancer patients were randomly assigned to observational group （n=41） and control group （n=40） after surgery. Patients in observational group received oxaliplatin＋S-1 regimen, while those in control group were treated with XEOLX regimen. Results： The 1- and 2-year recurrence-free survival （RFS） for observational group was 51.3% and 61.5%, and for control group was 25.6% and 20.5%, while the 1- and 2-year overall survival （OS） for observational group was 64.1% and 69.2%, and for control group was30.8% and 25.6% respectively, and all differences had no statistical significance （P=0.361, 0.591; P=0.631, 0.615）. The toxic and side effects seen in both groups were mainly myelosuppression, gastrointestinal reactions, hand-foot syndrome, oral mucositis, and peripheral neuropathy as well as hepatic and renal function damage, among which, the incidence of hand-foot syndrome in control group was significantly higher than that in observational group （P=0.001）; all the toxic and adverse reactions were resolved by symptomatic treatment. Conclusion： Oxaliplatin＋S-1 regimen has an efficacy equivalent to XELOX regimen in adjuvant chemotherapy for postoperative gastric cancer.